

Annals  
of  
Hepatology

# Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)

Stefano Bellentani,<sup>1</sup> Mariano Marino<sup>1</sup>

## Abstract

The authors summarize and update the most recent knowledge in the field of prevalence, natural history and incidence of Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steatohepatitis (NASH). These novel diseases, firstly recognized at the beginning of the second millennium, arose suddenly to the attention of the clinicians, because they are the hepatic expression of the "so-called" metabolic syndrome. Due to the epidemic burden of obesity, diabetes, and metabolic diseases, NAFLD and NASH will become soon probably the most common hepatic disease worldwide, and they surely will keep busy our future young hepatologists.

**Key words:** NAFLD, NASH, prevalence, incidence, natural history, epidemiology.

## Definition of NAFLD

The term NAFLD is used to describe a condition of fat accumulation in the liver in the absence of excessive alcohol consumption (less than 20 g per day) and any other specific causes of hepatic steatosis.<sup>1-5</sup> In the majority of the cases NAFLD is of primary origin and its aetiology is not yet completely understood, even if it is strictly related to the presence of insulin resistance, and thus frequently occurs as the initial part of the metabolic syndrome (MS), and accompany obesity, type 2 diabetes and dyslipidaemia.<sup>6-11</sup> Among the secondary causes of NAFLD there are relevant causes, such as nutritional (e.g. malnutrition, rapid weight loss), metabolic (e.g. abetal-

ipoproteinemia, lipodystrophy) and drug-induced (e.g. glucocorticoids, methotrexate, chemotherapies, tamoxifene, etc.), as well as other conditions (e.g. jejunal diverticulitis with bacterial overgrowth, inflammatory bowel disease, occupational exposure). In this review we are focusing our attention only to the epidemiology and natural history of primary NAFLD.

## Prevalence of NAFLD

NAFLD is now the most common liver disease in the United States and possibly worldwide. Furthermore, the number of affected patients is growing rapidly, and the disease has reached epidemic proportions. However, the true prevalence of NAFLD and Nonalcoholic-Steatohepatitis (NASH), and their natural history remains incompletely defined. Furthermore, there are no data on the change in prevalence of NAFLD within a population over time, and there are no data on incidence of NAFLD. The reported prevalence of NAFLD varies according to the population studied, and the diagnostic criteria used.<sup>12-14</sup> Usually population-based studies provide better estimates of the prevalence of NAFLD in the general population compared with autopsy studies, hospital series or studies performed exclusively in obese populations, but few such studies have been reported to date.<sup>15-17</sup> However, the diagnosis of NAFLD within the population studies are usually made by ultrasonography (US), that allows detecting moderate and severe steatosis with a fair sensitivity and specificity only when fat on liver biopsy exceeds 33%. More sensitive techniques, including MR imaging and spectroscopy, are hindered by expense and lack of feasibility in large populations. The American Association for the Study of Liver Diseases (AASLD) set the limit for the diagnosis of NAFLD at fat accumulation in the liver of at least 5 to 10% by weight. Therefore, liver biopsy is still considered as the gold standard, but is limited by sampling and interpretation error besides its cost and not applicability in population-based studies for both ethical and practical reasons.

*Table 1* summarizes the results of several studies on the prevalence of NAFLD/NASH.<sup>12-44</sup> Proton MR spectroscopy and <sup>1</sup>H-MRS are considered the most accurate non-invasive methods for measuring liver fat, but again impractical and too expensive to be applied on a

<sup>1</sup> Azienda USL di Modena – Liver and Nutrition Centre – "Ramazzini" Hospital Carpi, Modena, Italy.

Address for correspondence:  
Stefano Bellentani, M.D., Ph.D.  
Centro Studi Nutrizione e Fegato  
Azienda USL di Modena  
Poliambulatori Ospedale "B.Ramazzini"  
P.le Donatori di Sangue, 2  
41012 Carpi (Modena) – Italy  
E-mail: bellentanistefano@gmail.com  
s.bellentani@ausl.mo.it

**Table I.** Prevalence (=P) of Nonalcoholic Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) according to different type of studies. ND= not determined. See reference from 12 to 44.

Author (year)	Study	Diagnostic method	Country	NAFLD P (%)	NASH P (%)
Nomura (1988)	Population-based	Ultrasonography	Japan	14	ND
El-Hassan (1992)	Outpatients	Ultrasonography, CT	Saudi Arabia	10	ND
Tominaga (1995)	Health evaluation	Ultrasonography	Japan	3 (children)	ND
Franzese (1997)	Outpatients	Ultrasonography	Italy	53 (obese children)	ND
Lonardo (1997)	Outpatients	Ultrasonography	Italy	20	ND
Araujo (1998)	Outpatients	Ultrasonography	Brazil	33.5	ND
Bellentani (2000)	Population-based	Ultrasonography	Italy	16 (Lean) 76 (Obese)	ND
Omagari (2002)	Outpatients	Ultrasonography	Japan	9	ND
Bedogni (2005)	Population-based	Ultrasonography	Italy	23	ND
Fan (2005)	Population-based	Ultrasonography	China	15	ND
Jimba (2005)	Health evaluation	Ultrasonography	Japan	29	ND
Hamaguchi (2005)	Health evaluation	Ultrasonography	Japan	18	ND
Park (2006)	Health evaluation	Ultrasonography	South Korea	16	ND
Browning (2004)	Population-based	MR spectroscopy	USA	31	ND
Patt (2003)	Health evaluation	Aminotransferase	USA	14-21	ND
Clark (2003)	Population-based	Aminotransferases	USA	5.4	ND
Ruhl (2003)	Population-based	Aminotransferases	USA	2.8	ND
Hultcrantz (1986)	Hospital series	Liver biopsy	Sweden	39	ND
Lee (1989)	Hospital series	Liver biopsy	USA	ND	9
Nonomura (1992)	Hospital series	Liver biopsy	Japan	ND	1
Byron (1996)	Hospital series	Liver biopsy	USA	ND	11
Daniel (1999)	Hospital series	Liver biopsy	USA	51	32
Berasain (2000)	Hospital series	Liver biopsy	Spain	ND	16
Hilden (1977)	Autopsy series	Liver biopsy	Sweden	24	ND
Ground (1982)	Autopsy series	Liver biopsy	USA	16	ND
Wanless (1990)	Autopsy series	Liver biopsy	Canada	29	6
Schwimmer (2006)	Autopsy series	Liver biopsy	USA	9.6 (children) 38 (obese)	3
Luyckx (1998)	Bariatric surgery	Liver biopsy	Belgium	74	ND
Silverman (1990)	Bariatric surgery	Liver biopsy	USA	86	36
Dixon (2001)	Bariatric surgery	Liver biopsy	Australia	71	25
Beymer (2003)	Bariatric surgery	Liver biopsy	USA	85	33
Spaulding (2003)	Bariatric surgery	Liver biopsy	USA	88	56
Mathurin (2006)	Bariatric surgery	Liver biopsy	France	ND	14.4

large scale. Recently both the Dallas Heart Study (a population-based cohort study performed in an ethnically diverse community in the USA) and our Dionysos study (a population-based cohort study performed in 2 community of Northern of Italy) reported that 30% of adult Americans and 25% of adult Italians have NAFLD. This indicates that over 70 million adult Americans and 15 million adult Italians suffer from NAFLD. In that studies 79 and 55% of patients with NAFLD had normal aminotransferase levels, suggesting that studies using liver enzymes as a surrogate for NAFLD highly underestimate the prevalence of NAFLD.

NAFLD has also reached epidemic proportions among populations typically considered at "low risk" for this liver condition, with a prevalence in China and Japan of 15 and 14%, respectively, among adults. The clinical implications of this alarming prevalence of NAFLD are derived from the fact that this liver condition may progress to endstage liver disease and liver cancer. The prevalence of NAFLD among children is unknown, but some

data indicate that 2.6–9.6% of children have NAFLD, increasing up to 38–53% among obese children (*Table I*).

NAFLD is more frequent among obese subjects (75%) compared to controls (16%), and among patients with type 2 diabetes (34-74%), whereas it is an almost universal finding in obese patients with type 2 diabetes. The prevalence of NAFLD is also more prevalent in Hispanics and Asian-Indians than in white Americans or Black, and it is normally increasing with age. Recent data indicate a doubling of the prevalence in children: from 2.6% a decade ago to 5% today in normal-weight, and 38% or 48% in obese and diabetic children respectively. All these prevalences makes NAFLD the most common chronic liver disease in the Western societies.

### Natural history, mortality and incidence of NAFLD

Data on natural history and mortality of NAFLD/ NASH are contradictory and the study available in the

literature are not conclusive.<sup>48-64</sup> NAFLD progresses slowly to NASH and cirrhosis or HCC over many years or decades, therefore the natural history is difficult to measure in short-time interval. Patients with simple, bland steatosis seem to have a more benign prognosis. For instance, a Danish study by Dam-Larsen and co-workers<sup>65</sup> of a cohort of 109 predominantly morbidly obese subjects, followed for nearly 17 years, found the incidence of cirrhosis to be less than 1%, and during the follow-up the mortality of people with fatty liver did not differ from the general population mortality. Conversely, patients with cryptogenic cirrhosis due to NASH have a worse prognosis, as demonstrated in some recent studies where 9-26% of patients died within 4-10 years of follow-up, with most causes of death related to end-stage liver disease.<sup>66-70</sup> Using a community-based sample, Adams et al.<sup>66-67</sup> demonstrated a lower survival among persons with NAFLD compared to the general population. In a different study, Ekstedt et al.<sup>68</sup> showed that persons with NAFLD, in particular those with the subtype of NASH, had a reduced survival when compared with a matched reference population. Both these studies however may not necessarily reflect the general population. In the Dionysos cohort, after 8.5 years of follow up, we found that people with alcohol use or abuse remains still the main risk factor for progression of fatty liver to end-stage liver disease.<sup>23,69</sup> The last study available, published by Ong et al.<sup>70</sup> that used the NHANES III data-base, showed that persons with NAFLD have a higher likelihood of dying of a liver-related complication compared to those without NAFLD or liver disease. This risk was independent of obesity or the presence of diabetes mellitus, the latter being associated with higher rates of liver-related deaths. However, a great limitation of this study is the use of elevated serum aminotransferases as a marker of NAFLD, which underestimates the true prevalence of NAFLD of more than 50%, as already reported above.

Among the various causes of death in people with NAFLD, cardiovascular disease and malignancy seems to be the most important causes as found by Ong et al.,<sup>70</sup> but also by others previously published cohort studies. For this reason, NAFLD is now believed to be the hepatic manifestation of the metabolic syndrome, and an independent predictor of cardiovascular morbidity and mortality.

Overall, a diagnosis of NAFLD is associated with a shorter survival than expected for the general population of the same age and gender, and the higher mortality is mainly due to cardiovascular disease (CVD). A strong association between elevated levels of serum liver enzymes and increased CVD risk has also been reported by numerous population-based studies, such as the Hoorn Study, the Framingham Heart Study and the Valpolicella Heart Diabetes Study,<sup>71-73</sup> where mildly elevated levels of liver enzymes were independently associated with an increased CVD mortality rate in both sexes, independently

of traditional risk factors and components of the metabolic syndrome.

Long-term data that clearly show that NAFLD progress to end-stage liver disease are lacking, even if some short-term data suggest that NAFLD underlies a substantial proportion of cases of cryptogenic cirrhosis<sup>74,75</sup> of patients with cryptogenic cirrhosis, 50-73% are obese or suffer from diabetes. Further, the presence of NAFLD increases disease severity and progression in other liver diseases including chronic hepatitis C infection, alcoholic liver disease and hemochromatosis.

The incidence of NAFLD remains unknown because no prospective studies have been conducted. The only data available are the one referring to the incidence of fatty liver (FL) in the Dionysos cohort, where we found that FL regressed in nearly 1 of every 2 cases and had a substantially benign course, and ethanol intake was the most important risk factor for FL remission and incidence.<sup>23,76,77</sup> The incidence and remission rates of FL after 8.5 years of follow up in the Dionysos cohort were 18.5 and 55.0 per 1,000 person-years; every increase of 20 g/day of ethanol intake at baseline was associated with a 17% increase in the rate of incident FL.<sup>76</sup>

## Conclusions

NAFLD has become a common diagnosis in clinical practice of several medical specialties, and its prevalence in the general population is increasing together with obesity, type 2 diabetes and the metabolic syndrome. Bland steatosis remains stable for a number of years and will probably never progress in many cases. On the contrary in those patients with NASH, whose disease progresses to advanced fibrosis and cirrhosis, most liver and heart-related morbidity and mortality are observed. Prospective studies with long-term follow-up are necessary to better define the natural history of NAFLD and its incidence both in the general populations and in specific groups. Genetic studies are also necessary to determine to what extent the genetic background predisposes to NAFLD development and progression to advanced liver disease.

## References

1. Ludwig J, Viggiano T, McGill D, Ott B. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; 55: 434-438.
2. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* 1994; 107: 1103-1109.
3. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. *Hepatology* 1994; 20: 1442-1449.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of

- clinical and pathological severity. *Gastroenterology* 1999; 116: 1413-1419.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. *Hepatology* 2003; 37: 1202-1219.
  6. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med* 2002; 346: 1221-1231.
  7. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. *Clin Liver Dis* 2004; 8(3): 521-33.
  8. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. *Ann Intern Med* 2005; 143: 722-728.
  9. Angulo P. Nonalcoholic fatty liver disease. *Rev Gastroenterol Mex* 2005; 70 Suppl 3: 52-6.
  10. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. *J Nutr Biochem* 2007; 18(3): 184-95.
  11. Dunn W, Schwimmer JB. The obesity epidemic and nonalcoholic fatty liver disease in children. *Curr Gastroenterol Rep* 2008; 10(1): 67-72.
  12. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. *Ann Epidemiol* 2007; 17(11): 863-9.
  13. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. *Clin Liver Dis* 2007; 11(1): 1-16, vii.
  14. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2007; 25(8): 883-9.
  15. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. *Jpn J Med* 1988; 27: 521-528.
  16. El-Hassan AY, Ibrahim EM, al-Mulhim FA, Nabhan AA, Chammas MY. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. *Br J Radiol* 1992; 65(777): 774-778.
  17. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, Kusano Y. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. *Dig Dis Sci* 1995; 40(9): 2002-9.
  18. Franzese A, Vajro P, Argenziano A, Puziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. *Dig Dis Sci* 1997; 42(7): 1428-32.
  19. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. *Ital J Gastroenterol Hepatol* 1997; 29(4): 351-356.
  20. Araujo LM, De Oliveira DA, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. *Diabetes Metab* 1998; 24(5): 458-462.
  21. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. *Ann Intern Med* 2000; 132: 112-117.
  22. Omagari K, Kadokawa Y, Masuda JI, Egawa I, Sawa T, Hazama H, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. *J Gastroenterol Hepatol* 2002; 17: 1098-1105.
  23. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. *Hepatology* 2005; 42: 44-52.
  24. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. *J Hepatol* 2005; 43: 508-514.
  25. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. *Diabet Med* 2005; 22(9): 1141-5.
  26. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. *Ann Intern Med* 2005; 143(10): 722-8.
  27. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. *J Gastroenterol Hepatol* 2006; 21(1 Pt 1): 138-43.
  28. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; 40: 1387-1395.
  29. Patt CH, Yoo HY, Dibatj K, Flynn J, Thuluvath PJ. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. *Dig Dis Sci* 2003; 48(4): 797-801.
  30. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* 2003; 98(5): 960-967.
  31. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. *Gastroenterology* 2003; 124(1): 71-9.
  32. Hultcrantz R, Glaumann H, Lindberg G, and Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. *Scand J Gastroenterol* 1986; 21(1): 109-113.
  33. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. *Hum Pathol* 1989; 20: 594-598.
  34. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholic steatohepatitis and fibrosis. *Gastroenterol Jpn* 1992; 27: 521-528.
  35. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. *Hepatology* 1996; 24(4): 813-5.
  36. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. *Am J Gastroenterol* 1999; 94(10): 3010-3014.
  37. Berasain C, Betes M, Panizo A, Ruiz J, Herrero JJ, Civeira MP, Prieto J. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. *Gut* 2000; 47(3): 429-435.
  38. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a "normal" population—examinations of 503 consecutive fatal traffic casualties. *Scand J Gastroenterol* 1977; 12(5): 593-597.
  39. Ground KE. Liver pathology in aircrew. *Aviat Space Environ Med* 1982; 53(1): 14-18.
  40. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology* 1990; 12(5): 1106-10.
  41. Schwimmer J, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; 118: 1388.
  42. Luyckx FH, Desai C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefèbvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. *Int J Obes Relat Metab Disord* 1998; 22(3): 222-6.
  43. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF. Liver pathology in morbidly obese patients with and without diabetes. *Am J Gastroenterol* 1990; 85(10): 1349-55.
  44. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology* 2001; 121(1): 91-100.
  45. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. *Arch Surg* 2003; 138(11): 1240-4.
  46. Spaulding L, Trainer T, Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. *Obes Surg* 2003; 13(3): 347-9.



47. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, Louvet A, Dharancy S, Cocq P, Jany T, Boitard J, Deltenre P, Romon M, Pattou F. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. *Gastroenterology* 2006; 130(6): 1617-24.
48. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis (Letter). *Gastroenterology* 1995; 108(5): 1607.
49. Teli MR, James OFW, Burt AD, Bennett MK, CP Day. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology* 1995; 22: 1714-1719.
50. Sheth SG, Gordon FD, Chopra S. Non-alcoholic steatohepatitis. *Ann Intern Med* 1997; 126: 137-145.
51. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. *Semin Liver Dis* 2001; 21: 17-26.
52. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. *J Hepatol* 2001; 35: 531-537.
53. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001; 50: 1844-1850.
54. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. *Rev Gastroenterol Disord* 2002; 2(1): 11-19.
55. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. *J Gastroenterol Hepatol* 2002; 17: 1136-1143.
56. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology* 2002; 123: 134-140.
57. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? *Gut* 2002; 50: 585-588.
58. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. *Gastroenterology* 2003; 124(1): 248-250.
59. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. *Am J Gastroenterol* 2003; 98: 2042.
60. Alba LM, Lindor K. Non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2003; 17(8): 977-86.
61. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. *Gastroenterology* 2005; 129: 375-378.
62. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. *Hepatol Res* 2005; 33: 72-76.
63. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. *JAMA* 2003; 289: 3000.
64. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. *Hepatology* 2006; 43: 682-689.
65. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut* 2004; 53: 750-755.
66. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. *Gastroenterology* 2005; 129: 113-121.
67. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. *J Hepatol* 2005; 42: 12-14.
68. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; 44: 865-873.
69. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol* 2006; 6: 33-38.
70. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. *J Hepatol* 2008; 49(4): 608-12.
71. Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. *Atherosclerosis* 2007; 191: 391-396.
72. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. *Gastroenterology* 2008; 135(6): 1935-44.
73. Targher G, Bertolini L, Tessari R, Zenari L, Arcaro G. The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. *The Valpolicella Heart Diabetes Study. Diabet Med* 2006; 23(11): 1270-1.
74. Ratzliff V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. *Hepatology* 2006; 44: 802-805.
75. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study. *Am J Gastroenterol* 2008 [Epub ahead of print].
76. Bedogni G, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: the Dionysos study. *Hepatology* 2007; 46: 1387-1391.
77. Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, Crocè LS, Granito A, Tiribelli C, Bellentani S. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. *Am J Gastroenterol* 2008; 103(9): 2248-53.